Is Thymosin Alpha-1 Legal in South Carolina?

HealthRX.com

No federal approval for thymosin alpha-1, and SC rules are unclear

Print or save as PDF

  • FDA approval / None in the US; orphan designations are not approvals [1]
  • Pharmacy compounding list / Not in any of the three categories for state-licensed pharmacies and physicians [2]
  • Outsourcing facilities / Category 3, 'nominated without adequate support' [3]
  • FDA advisory vote / 4 yes, 17 no on adding it to the pharmacy bulks list [4]
  • HHS peptide draft / Not among the six peptides in the October 2026 draft policy [5]
  • Other countries / Approved in Italy, India and Hong Kong [1]

What is the federal legal position?

Thymosin alpha-1, also called thymalfasin, has no FDA-approved application [1]. FDA's December 2024 review notes four US orphan drug designations, but orphan designation is a separate process from approval and is not an approval [1]. Zadaxin is the brand of the finished injection sold outside the US and is not interchangeable with bulk thymosin alpha-1 powder [1].

FDA's list for state-licensed pharmacies and physicians does not include thymosin alpha-1 in any of its three categories [2]. On FDA's list for outsourcing facilities, it is in category 3, 'nominated without adequate support' [3]. FDA's category 1 policy, which generally says the agency will not act against compounders if conditions are met, does not apply to it [2][3].

In December 2024, FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and acetate forms. Members who voted no cited no compelling evidence of clinical effectiveness and safety [4]. FDA had proposed that thymosin alpha-1 not be added to the pharmacy bulks list [4].

Does FDA still list safety concerns?

Yes. FDA's page on bulk substances that may raise significant safety risks lists thymosin alpha-1 in the 'nominated but withdrawn' table. It had been in category 2, and it came off because the nominators withdrew. FDA's stated concerns remain: significant risk for immunogenicity for certain routes of administration, peptide-impurity and characterization problems, and safety information that FDA called inadequate to understand the extent of any safety issues [6].

Thymosin alpha-1 is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [5].

Is it approved outside the US?

Yes. FDA's December 2024 review lists Italy, where Zadaxin is authorized as an adjuvant to influenza vaccination in immunocompromised people; India, for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication; and Hong Kong [1]. Those approvals are not US approvals [1].

What about South Carolina?

The federal picture is the same in South Carolina as elsewhere: thymosin alpha-1 is not FDA-approved [1], it is not listed for state-licensed pharmacy compounding [2], and it is in category 3 for outsourcing facilities [3]. FDA's information does not say whether South Carolina has a separate statute, Board of Pharmacy rule or Board of Medical Examiners guidance that names thymosin alpha-1.

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. How did FDA's Pharmacy Compounding Advisory Committee vote in December 2024 on the free base and acetate forms?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Questions worth asking

Choose the questions you want to keep

What is the federal status of thymosin alpha-1?
It is not FDA-approved. FDA's review notes four US orphan drug designations, which are not approvals [1]. It is also not in any of the three categories on FDA's list for state-licensed pharmacies [2].
Did FDA's advisory committee support compounding thymosin alpha-1?
No. In December 2024 the Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and acetate forms [4].
Does FDA still list safety concerns for thymosin alpha-1?
Yes. It is in FDA's nominated-but-withdrawn table, and FDA's concerns about immunogenicity, peptide impurities and inadequate safety information remain posted [6].
Is thymosin alpha-1 approved in other countries?
Yes. FDA's December 2024 review lists Italy, India and Hong Kong, with different authorized uses [1]. Those are not US approvals.
Is thymosin alpha-1 in the HHS peptide policy?
No. It is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [5].
Is thymosin alpha-1 on the WADA Prohibited List?
It is not named on WADA's 2026 Prohibited List [7]. WADA does name thymosin-beta-4 and derivatives such as TB-500, which are different peptides [7].
Show all 7 referencesHide references
Evidence overview for Is Thymosin Alpha-1 Legal in South Carolina?